Literature DB >> 11517321

The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.

I B Rasmussen1, E Lunde, T E Michaelsen, B Bogen, I Sandlie.   

Abstract

Targeting of antigens to antigen-presenting cells (APCs) increases CD4(+) T cell activation, and this observation can be exploited in the development of new vaccines. We have chosen an antigen-targeting approach in which we make recombinant antibodies (Abs) with T cell epitopes in their constant region and APC-specific variable regions. Three commonly used model epitopes, amino acids 110-120 of hemagglutinin, 323-339 of ovalbumin, and 46-61 of hen egg lysozyme, were introduced as loops in the C(H)1 domain of human IgG3. For all three epitopes, we show that the recombinant molecules are secreted from transfected cells. The epitopes are presented to specific T cells, and targeting to IgD on B cells in vitro enhances the presentation efficiency by 10(4) to 10(5) compared with the free peptide. After i.v. injection, the epitopes targeted to IgD are presented by splenic APCs to activate specific T cells, whereas little or no activation could be detected without targeting, even after the amount of antigen injected was increased 100-fold or more. Because a wide variety of T cell epitopes, in terms of both length and secondary structure, can be tolerated in loops in constant domains of Abs, the Ab constant region seems to have the intrinsic stability that is needed for this fusion molecule strategy. It might thus be possible to load the Ab with several different epitopes in loops in different domains and thereby make a targeted multisubunit vaccine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517321      PMCID: PMC56955          DOI: 10.1073/pnas.181336898

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  68 in total

1.  Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells.

Authors:  L Norderhaug; T Olafsen; T E Michaelsen; I Sandlie
Journal:  J Immunol Methods       Date:  1997-05-12       Impact factor: 2.303

2.  Recombinant antibodies containing an engineered B-cell epitope capable of eliciting conformation-specific antibody responses.

Authors:  J Cook; B H Barber
Journal:  Vaccine       Date:  1995-12       Impact factor: 3.641

Review 3.  Immunogenicity of viral epitopes expressed on genetically and enzymatically engineered immunoglobulins.

Authors:  C A Bona; A Bot; T D Brumeanu
Journal:  Chem Immunol       Date:  1997

4.  Engineering vaccines with heterologous B and T cell epitopes using immunoglobulin genes.

Authors:  S Xiong; M Gerloni; M Zanetti
Journal:  Nat Biotechnol       Date:  1997-09       Impact factor: 54.908

5.  Sequences outside a minimal immunodominant site exert negative effects on recognition by staphylococcal nuclease-specific T cell clones.

Authors:  M S Vacchio; J A Berzofsky; U Krzych; J A Smith; R J Hodes; A Finnegan
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

6.  T cell recognition of endogenous IgG2a expressed in B lymphoma cells.

Authors:  E K Bikoff; H Yu; L A Eckhardt
Journal:  Eur J Immunol       Date:  1988-03       Impact factor: 5.532

7.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

8.  Engineering of doubly antigenized immunoglobulins expressing T and B viral epitopes.

Authors:  T D Brumeanu; A Bot; C A Bona; P Dehazya; I Wolf; H Zaghouani
Journal:  Immunotechnology       Date:  1996-06

9.  An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies.

Authors:  D J Evans; J McKeating; J M Meredith; K L Burke; K Katrak; A John; M Ferguson; P D Minor; R A Weiss; J W Almond
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

10.  The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing.

Authors:  W Jiang; W J Swiggard; C Heufler; M Peng; A Mirza; R M Steinman; M C Nussenzweig
Journal:  Nature       Date:  1995-05-11       Impact factor: 49.962

View more
  8 in total

1.  Time for T?: Thoughts about the 2009 novel H1N1 influenza outbreak and the role of T cell epitopes in the next generation of influenza vaccines.

Authors:  Anne S De Groot; Elizabeth McClaine; Lenny Moise; William Martin
Journal:  Hum Vaccin       Date:  2010-02-19

2.  Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus.

Authors:  Brian C Schanen; Anne S De Groot; L Moise; Matt Ardito; Elizabeth McClaine; William Martin; Vaughan Wittman; William L Warren; Donald R Drake
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

3.  DNA vaccines: MHC II-targeted vaccine protein produced by transfected muscle fibres induces a local inflammatory cell infiltrate in mice.

Authors:  Tom-Ole Løvås; Jo C Bruusgaard; Inger Øynebråten; Kristian Gundersen; Bjarne Bogen
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

4.  In Vivo Validation of Predicted and Conserved T Cell Epitopes in a Swine Influenza Model.

Authors:  Andres H Gutiérrez; Crystal Loving; Leonard Moise; Frances E Terry; Susan L Brockmeier; Holly R Hughes; William D Martin; Anne S De Groot
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

5.  Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.

Authors:  J Benjamin St Clair; Thiago Detanico; Katja Aviszus; Greg A Kirchenbaum; Merry Christie; John F Carpenter; Lawrence J Wysocki
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

6.  Antigen-armed antibodies against B-cell malignancies.

Authors:  Marta Ilecka; Dwain G van Zyl; Henri-Jacques Delecluse
Journal:  Oncotarget       Date:  2018-11-02

7.  Targeted Stat2 deletion in conventional dendritic cells impairs CTL responses but does not affect antibody production.

Authors:  Connie C Qiu; Kevin P Kotredes; Tess Cremers; Sajan Patel; Alexandra Afanassiev; Michael Slifker; Stefania Gallucci; Ana M Gamero
Journal:  Oncoimmunology       Date:  2020-12-29       Impact factor: 8.110

8.  Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.

Authors:  Agnete B Fredriksen; Inger Sandlie; Bjarne Bogen
Journal:  Front Oncol       Date:  2012-10-30       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.